<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399736</url>
  </required_header>
  <id_info>
    <org_study_id>Compare-Acute</org_study_id>
    <nct_id>NCT01399736</nct_id>
  </id_info>
  <brief_title>Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.</brief_title>
  <acronym>CompareAcute</acronym>
  <official_title>Fractional Flow Reserve Guided Primary Multivessel Percutaneous Coronary Intervention to Improve Guideline Indexed Actual Standard of Care for Treatment of ST-elevation Myocardial Infarction in Patients With Multivessel Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maasstad Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Compare-Acute trial is a prospective randomised trial in patients with multivessel
      disease, who are admitted into hospital with a ST-elevation Myocardial Infarction. The
      purpose of the study is to compare a FFR guided multivessel PCI taking place during the
      primary PCI with a primary PCI of the culprit vessel only.

      Patients will be enrolled after successful revascularisation of the culprit vessel. Patients
      that have at least one lesion with a diameter of stenosis of more than 50% on visual
      estimation, feasible (operators judgement) for treatment with PCI in a non-infarct related
      artery, will be randomised either to the FFR guided complete revascularisation arm or staged
      revascularisation by proven ischemia or persistence of symptoms of angina.

      Approximately 885 patients will be entered in the study.

      Study hypothesis: FFR-guided complete percutaneous revascularisation of all flow-limiting
      stenoses in the non-IRA performed within the same procedure as the primary PCI or within the
      same hospitalisation will improve clinical outcomes compared to the staged revascularisation,
      guided by prove of ischemia or clinical judgment, as recommended from the guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study: At the moment the general opinion is divided over the way the non
      culprit lesions in patients presenting with STEMI should be treated. While the previous
      guidelines stead that these lesions should be treated in a second time ( ie not during the
      primary intervention) the actual guidelines do not touch this argument. The reason is that
      the studies where the previous guidelines were based are old. Meanwhile small sized
      randomised trials from EU region have proven favourable outcomes with NON infarct related
      artery during the primary procedure while registers (non randomised trials) from USA still
      recommend the staged treatment. For this reason we have decided to perform a randomised study
      to address this issue incorporating the state of the art diagnosis and treatment, as well as
      the new medical therapy and PCI techniques.

      Objective of the study: FFR-guided complete percutaneous revascularisation of all
      flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI
      or within the same hospitalisation will improve clinical outcomes compared to the staged
      revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the
      guidelines

      Study design: Prospective, 1: 2 randomisation. FFR guided revascularisation during primary
      PCI (1) versus following actual guidelines (2)

      Study population: All STEMI patients between 18-85 years who will be treated with primary PCI
      in &lt; 12 h (more than 12 hr if persisting pain allowed) after the onset of symptoms and have
      at least one stenosis of &gt;50% in a non-IRA judged feasible for treatment with PCI.

      Intervention (if applicable): FFR-guided complete percutaneous revascularisation of all
      flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI
      or within the same hospitalisation will improve clinical outcomes compared to the staged
      revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the
      guidelines

      Primary study parameters/outcome of the study: Composite endpoint of all cause mortality
      non-fatal Myocardial Infarction, any Revascularisation and Stroke (MACCE) at 12 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With the Composite Endpoint of MACCE</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with the composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Cerebrovascular Events (MACCE) at 12 months between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Death From Any Cause</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with all cause mortality at 12 months between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cardiac Death</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with Cardiac mortality at 12 months between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Spontaneous MI</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with Spontaneous Myocardial Infarction at 12 months between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Periprocedural MI</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with Periprocedural Myocardial Infarction at 12 months between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Revascularization - PCI</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with revascularization PCI at 12 months between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Revascularization - CABG</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with revascularization CABG at 12 months between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cerebrovascular Event</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with Cerebrovascular event at 12 months between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of NACE (Any First Event)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 12 months (NACE i.e. Net Adverse Clinical Events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death From Any Cause or MI</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with Major bleeding at 12 months - Part of composite NACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Bleeding at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with any bleeding at 12 months - part of composite endpoint NACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Bleeding at 48 Hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of participants with any bleeding at 48 hours - part of composite endpoint NACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with hospitalization for heart failure, unstable angina or chest pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with any revascularization-Part of composite endpoint NACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with Stent Thrombosis - Part of composite endpoint NACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Primary Endpoint Outcome MACCE (Any First Event) at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Composite primary endpoint MACCE (any first event) at 3 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Cause Death at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - all cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Spontaneous MI at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Spontaneous MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Peri-procedural MI at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Peri-procedural MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urgent Revascularization at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - urgent revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Elective Revascularization at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year -elective revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cerebrovascular Event</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year -Cerebrovascular event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of NACE (Any First Event) at 3 Year</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 3 year (NACE i.e. Net Adverse Clinical Events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death From Any Cause or MI</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 3 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Bleeding at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Part of composite endpoint NACE- Major bleeding at 3 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalization</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Hospitalization for heart failure, unstable angina, MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalization at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Hospitalization for heart failure, unstable angina, MI and/or chest pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with Stent Thrombosis at 3 year - Part of composite endpoint NACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Bleeding at 3 Year</measure>
    <time_frame>3 year</time_frame>
    <description>Number of participants with any bleeding at 3 year - Part of composite endpoint NACE</description>
  </secondary_outcome>
  <other_outcome>
    <measure>A Comparison of the Number of Patients in Both Groups With Treated Lesions With FFR ≤ 0.80 Versus Patients With Untreated Lesions With FFR ≤ 0.80;</measure>
    <time_frame>3 year</time_frame>
    <description>FFR+/PCI+ vs FFR+/PCI- Comparison of patients having FFR positive lesions that underwent revascularization during index procedure or in staged procedures within 45 days (groups A+C, n=202 patients) with patients having FFR positive lesions that did not undergo revascularization (group D, n=231 patients),</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of Acute Versus Staged PCI for Lesions With FFR ≤ 0.80</measure>
    <time_frame>3 year</time_frame>
    <description>Comparison of acute versus staged PCI treatment for lesions with FFR</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of PCI vs Medical Therapy in FFR Negative Lesions</measure>
    <time_frame>3 year</time_frame>
    <description>comparison of patients receiving staged PCI treatment of FFR-negative lesions in the non-IRA (decision made by referring physician who was blinded to FFR results) and patients receiving medical therapy for FFR-negative lesions in the non-IRA</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">885</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Multivessel Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>FFR-guided revascularisation strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>randomised to guidelines group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FFR-guided revascularisation strategy</intervention_name>
    <description>FFR-guided revascularisation strategy</description>
    <arm_group_label>FFR-guided revascularisation strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>randomised to guidelines group</intervention_name>
    <description>Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
    <arm_group_label>randomised to guidelines group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients between 18-85 years presenting with STEMI who will be treated with
             primary PCI in &lt; 12 h after the onset of symptoms* and have at least one stenosis of
             &gt;50% in a non-IRA on QCA or visual estimation of baseline angiography and judged
             feasible for treatment with PCI by the operator.

               -  Patients with symptoms for more than 12 hr but ongoing angina complaints can be
                  randomised

        Exclusion Criteria:

          1. Left main stem disease (stenosis &gt; 50%)

          2. STEMI due to in-stent thrombosis

          3. Chronic total occlusion of a non-IRA

          4. Severe stenosis with TIMI flow ≤ II of the non-IRA artery.

          5. Non-IRA stenosis not amenable for PCI treatment (operators decision)

          6. Complicated IRA treatment, with one or more of the following;

               -  Extravasation,

               -  Permanent no re-flow after IRA treatment (TIMI flow 0-1),

               -  Inability to implant a stent

          7. Known severe cardiac valve dysfunction that will require surgery in the follow-up
             period.

          8. Killip class III or IV already at presentation or at the completion of culprit lesion
             treatment.

          9. Life expectancy of &lt; 2 years.

         10. Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Bivaluridin, or
             Everolimus and known true anaphylaxis to prior contrast media of bleeding diathesis or
             known coagulopathy.

         11. Gastrointestinal or genitourinary bleeding within the prior 3 months,

         12. Planned elective surgical procedure necessitating interruption of thienopyridines
             during the first 6 months post enrolment.

         13. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period.

         14. Pregnancy or planning to become pregnant any time after enrolment into this study.

         15. Inability to obtain informed consent.

         16. Expected lost to follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Smits, MD. PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastadhospital / MCR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elmir Omerovic, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska Hospital Götheborg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gert Richardt, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Herzzentrum Segeberger Kliniken</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franz-Josef Neumann, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Herz-Zentrum Bad Krozingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital BRNO</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberec Regional Hospital</name>
      <address>
        <city>Liberec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Segeberger Klinik</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Links der Weser</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik IV</name>
      <address>
        <city>Ingolstadt</city>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Országos Kardiológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs - Szatmár - Bereg County Hospitals and University Teaching Hospital</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent-Györgyi Albert Klinika</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Korhaz</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC Parkstad</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medical center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstadhospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>The Hague</city>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miedziowe Centrum Zdrowia Lubin</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawie</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniki Kardiologii Allenort</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khoo Teck Puat Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>768828</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Götheborg University Hospital</name>
      <address>
        <city>Goteborg</city>
        <zip>41315</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Luxembourg</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <results_first_submitted>May 14, 2020</results_first_submitted>
  <results_first_submitted_qc>July 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2020</results_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCI FFR STEMI MVD</keyword>
  <keyword>FFR guided PCI in acute STEMI patients with MVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 18, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT01399736/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FFR-guided Revascularisation Strategy</title>
          <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
        </group>
        <group group_id="P2">
          <title>Randomised to Guidelines Group</title>
          <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="590"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="586"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>885 patients with STEMI and multivessel disease</population>
      <group_list>
        <group group_id="B1">
          <title>FFR-guided Revascularisation Strategy</title>
          <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
        </group>
        <group group_id="B2">
          <title>Randomised to Guidelines Group</title>
          <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="295"/>
            <count group_id="B2" value="590"/>
            <count group_id="B3" value="885"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="10"/>
                    <measurement group_id="B2" value="61" spread="10"/>
                    <measurement group_id="B3" value="62" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="450"/>
                    <measurement group_id="B3" value="683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Collection of race has been done, but only specified as white race and other</description>
          <population>information missing for 1 patient</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>white race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="589"/>
                    <count group_id="B3" value="884"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="545"/>
                    <measurement group_id="B3" value="808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other races</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" lower_limit="18.0" upper_limit="44.1"/>
                    <measurement group_id="B2" value="27.1" lower_limit="17.7" upper_limit="54.3"/>
                    <measurement group_id="B3" value="27.1" lower_limit="17.7" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>current smoker</title>
          <population>information about smoking missing for few patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="294"/>
                    <count group_id="B2" value="589"/>
                    <count group_id="B3" value="883"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypercholesterolemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of premature coronary artery disease</title>
          <population>information missing for 1 patient</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="294"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="884"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous stroke</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Myocardial Infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous PCI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Impairment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peripheral vessel disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of infarct - Posterior</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of infarct - Anterior</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of infarct - Inferior</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="307"/>
                    <measurement group_id="B3" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of infarct - Lateral</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of infarct - impossible to determine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from symptom onset to primary PCI &lt; 6 hr</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="462"/>
                    <measurement group_id="B3" value="687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from symptom onset to primary PCI 6-12 hr</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from symptom onset to primary PCI &gt;12 hr</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nr. of arteries with stenosis 2</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="396"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nr. of arteries with stenosis 3</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Killip class &gt;=2</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum creatinine kinase level</title>
          <units>IU/liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1040" lower_limit="102" upper_limit="8182"/>
                    <measurement group_id="B2" value="1125" lower_limit="112" upper_limit="11052"/>
                    <measurement group_id="B3" value="1083" lower_limit="102" upper_limit="11052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean time for index procedure - min</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="31"/>
                    <measurement group_id="B2" value="59" spread="28"/>
                    <measurement group_id="B3" value="61" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean volume of contract used during index PCI</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224" spread="104"/>
                    <measurement group_id="B2" value="202" spread="75"/>
                    <measurement group_id="B3" value="209" spread="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FFR procedure successful</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="575"/>
                    <measurement group_id="B3" value="867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with lesions FFR&lt;=0.80</title>
          <population>FFR not performed in all patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                    <count group_id="B2" value="575"/>
                    <count group_id="B3" value="867"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with lesions FFR&gt;0.80</title>
          <population>FFR not performed in all patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                    <count group_id="B2" value="575"/>
                    <count group_id="B3" value="867"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean FFR value</title>
          <population>FFR not performed in all patients</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="882"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.78" spread="0.12"/>
                    <measurement group_id="B2" value="0.79" spread="0.12"/>
                    <measurement group_id="B3" value="0.78" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions during index PCI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions delayed during index hospitalization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions - DES only</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions - bare metal stent only</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions - balloon dilatation only</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions - mean nr. of stents used per patient</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="0.9"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions -mean length of stent</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" spread="21.0"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="34.3" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with treated (FFR-guided) non-IRA lesions - mean diameter of stent</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="0.4"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="2.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>length of hospital stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="1" upper_limit="35"/>
                    <measurement group_id="B2" value="4" lower_limit="1" upper_limit="71"/>
                    <measurement group_id="B3" value="4" lower_limit="1" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients receiving predischarge noninvasive stress tests</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="295"/>
                    <count group_id="B2" value="590"/>
                    <count group_id="B3" value="885"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Composite Endpoint of MACCE</title>
        <description>Number of participants with the composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Cerebrovascular Events (MACCE) at 12 months between groups</description>
        <time_frame>12 months</time_frame>
        <population>Patients with STEMI and multivessel disease</population>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Composite Endpoint of MACCE</title>
          <description>Number of participants with the composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Cerebrovascular Events (MACCE) at 12 months between groups</description>
          <population>Patients with STEMI and multivessel disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Death From Any Cause</title>
        <description>Number of participants with all cause mortality at 12 months between groups</description>
        <time_frame>12 months</time_frame>
        <population>Patients with STEMI and multivessel disease</population>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death From Any Cause</title>
          <description>Number of participants with all cause mortality at 12 months between groups</description>
          <population>Patients with STEMI and multivessel disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cardiac Death</title>
        <description>Number of participants with Cardiac mortality at 12 months between groups</description>
        <time_frame>12 months</time_frame>
        <population>Patients with STEMI and multivessel disease</population>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death</title>
          <description>Number of participants with Cardiac mortality at 12 months between groups</description>
          <population>Patients with STEMI and multivessel disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Spontaneous MI</title>
        <description>Number of participants with Spontaneous Myocardial Infarction at 12 months between groups</description>
        <time_frame>12 months</time_frame>
        <population>Patients with STEMI and multivessel disease</population>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Spontaneous MI</title>
          <description>Number of participants with Spontaneous Myocardial Infarction at 12 months between groups</description>
          <population>Patients with STEMI and multivessel disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Periprocedural MI</title>
        <description>Number of participants with Periprocedural Myocardial Infarction at 12 months between groups</description>
        <time_frame>12 months</time_frame>
        <population>Patients with STEMI and multivessel disease</population>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Periprocedural MI</title>
          <description>Number of participants with Periprocedural Myocardial Infarction at 12 months between groups</description>
          <population>Patients with STEMI and multivessel disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Revascularization - PCI</title>
        <description>Number of participants with revascularization PCI at 12 months between groups</description>
        <time_frame>12 months</time_frame>
        <population>Patients with STEMI and multivessel disease</population>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Revascularization - PCI</title>
          <description>Number of participants with revascularization PCI at 12 months between groups</description>
          <population>Patients with STEMI and multivessel disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Revascularization - CABG</title>
        <description>Number of participants with revascularization CABG at 12 months between groups</description>
        <time_frame>12 months</time_frame>
        <population>Patients with STEMI and multivessel disease</population>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Revascularization - CABG</title>
          <description>Number of participants with revascularization CABG at 12 months between groups</description>
          <population>Patients with STEMI and multivessel disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>5.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cerebrovascular Event</title>
        <description>Number of participants with Cerebrovascular event at 12 months between groups</description>
        <time_frame>12 months</time_frame>
        <population>Patients with STEMI and multivessel disease</population>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cerebrovascular Event</title>
          <description>Number of participants with Cerebrovascular event at 12 months between groups</description>
          <population>Patients with STEMI and multivessel disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of NACE (Any First Event)</title>
        <description>Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 12 months (NACE i.e. Net Adverse Clinical Events)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of NACE (Any First Event)</title>
          <description>Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 12 months (NACE i.e. Net Adverse Clinical Events)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death From Any Cause or MI</title>
        <description>Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 12 months</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death From Any Cause or MI</title>
          <description>Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 12 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Bleeding</title>
        <description>Number of participants with Major bleeding at 12 months - Part of composite NACE</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Bleeding</title>
          <description>Number of participants with Major bleeding at 12 months - Part of composite NACE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Bleeding at 12 Months</title>
        <description>Number of participants with any bleeding at 12 months - part of composite endpoint NACE</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Bleeding at 12 Months</title>
          <description>Number of participants with any bleeding at 12 months - part of composite endpoint NACE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Bleeding at 48 Hours</title>
        <description>Number of participants with any bleeding at 48 hours - part of composite endpoint NACE</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Bleeding at 48 Hours</title>
          <description>Number of participants with any bleeding at 48 hours - part of composite endpoint NACE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalization</title>
        <description>Number of participants with hospitalization for heart failure, unstable angina or chest pain</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospitalization</title>
          <description>Number of participants with hospitalization for heart failure, unstable angina or chest pain</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Revascularization</title>
        <description>Number of participants with any revascularization-Part of composite endpoint NACE</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Revascularization</title>
          <description>Number of participants with any revascularization-Part of composite endpoint NACE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis</title>
        <description>Number of participants with Stent Thrombosis - Part of composite endpoint NACE</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis</title>
          <description>Number of participants with Stent Thrombosis - Part of composite endpoint NACE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Primary Endpoint Outcome MACCE (Any First Event) at 3 Year</title>
        <description>Number of participants with Composite primary endpoint MACCE (any first event) at 3 year</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Primary Endpoint Outcome MACCE (Any First Event) at 3 Year</title>
          <description>Number of participants with Composite primary endpoint MACCE (any first event) at 3 year</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Cause Death at 3 Year</title>
        <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - all cause death</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Cause Death at 3 Year</title>
          <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - all cause death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death at 3 Year</title>
        <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Cardiac death</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death at 3 Year</title>
          <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Cardiac death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Spontaneous MI at 3 Year</title>
        <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Spontaneous MI</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Spontaneous MI at 3 Year</title>
          <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Spontaneous MI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Peri-procedural MI at 3 Year</title>
        <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Peri-procedural MI</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peri-procedural MI at 3 Year</title>
          <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - Peri-procedural MI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urgent Revascularization at 3 Year</title>
        <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - urgent revascularisation</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urgent Revascularization at 3 Year</title>
          <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year - urgent revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Elective Revascularization at 3 Year</title>
        <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year -elective revascularisation</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Elective Revascularization at 3 Year</title>
          <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year -elective revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cerebrovascular Event</title>
        <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year -Cerebrovascular event</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cerebrovascular Event</title>
          <description>Number of participants with Composite endpoint MACCE (any first event) at 3 year -Cerebrovascular event</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of NACE (Any First Event) at 3 Year</title>
        <description>Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 3 year (NACE i.e. Net Adverse Clinical Events)</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of NACE (Any First Event) at 3 Year</title>
          <description>Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 3 year (NACE i.e. Net Adverse Clinical Events)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death From Any Cause or MI</title>
        <description>Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 3 year</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death From Any Cause or MI</title>
          <description>Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 3 year</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Bleeding at 3 Year</title>
        <description>Number of participants with Part of composite endpoint NACE- Major bleeding at 3 year</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Bleeding at 3 Year</title>
          <description>Number of participants with Part of composite endpoint NACE- Major bleeding at 3 year</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalization</title>
        <description>Number of participants with Hospitalization for heart failure, unstable angina, MI</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospitalization</title>
          <description>Number of participants with Hospitalization for heart failure, unstable angina, MI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalization at 3 Year</title>
        <description>Number of participants with Hospitalization for heart failure, unstable angina, MI and/or chest pain</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospitalization at 3 Year</title>
          <description>Number of participants with Hospitalization for heart failure, unstable angina, MI and/or chest pain</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis at 3 Year</title>
        <description>Number of participants with Stent Thrombosis at 3 year - Part of composite endpoint NACE</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis at 3 Year</title>
          <description>Number of participants with Stent Thrombosis at 3 year - Part of composite endpoint NACE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Bleeding at 3 Year</title>
        <description>Number of participants with any bleeding at 3 year - Part of composite endpoint NACE</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR-guided Revascularisation Strategy</title>
            <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
          </group>
          <group group_id="O2">
            <title>Randomised to Guidelines Group</title>
            <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Bleeding at 3 Year</title>
          <description>Number of participants with any bleeding at 3 year - Part of composite endpoint NACE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>A Comparison of the Number of Patients in Both Groups With Treated Lesions With FFR ≤ 0.80 Versus Patients With Untreated Lesions With FFR ≤ 0.80;</title>
        <description>FFR+/PCI+ vs FFR+/PCI- Comparison of patients having FFR positive lesions that underwent revascularization during index procedure or in staged procedures within 45 days (groups A+C, n=202 patients) with patients having FFR positive lesions that did not undergo revascularization (group D, n=231 patients),</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR+ and PCI+</title>
            <description>patients having FFR positive lesions that underwent revascularization during index procedure or in staged procedures within 45 days</description>
          </group>
          <group group_id="O2">
            <title>FFR+ and PCI-</title>
            <description>patients having FFR positive lesions that did not undergo revascularization</description>
          </group>
        </group_list>
        <measure>
          <title>A Comparison of the Number of Patients in Both Groups With Treated Lesions With FFR ≤ 0.80 Versus Patients With Untreated Lesions With FFR ≤ 0.80;</title>
          <description>FFR+/PCI+ vs FFR+/PCI- Comparison of patients having FFR positive lesions that underwent revascularization during index procedure or in staged procedures within 45 days (groups A+C, n=202 patients) with patients having FFR positive lesions that did not undergo revascularization (group D, n=231 patients),</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Comparison of Acute Versus Staged PCI for Lesions With FFR ≤ 0.80</title>
        <description>Comparison of acute versus staged PCI treatment for lesions with FFR</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Treatment FFR+</title>
            <description>Patients with acute PCI treatment for lesions with FFR ≤ 0.80</description>
          </group>
          <group group_id="O2">
            <title>Staged Treatement FFR+</title>
            <description>Patients with staged PCI treatment for lesions with FFR ≤ 0.80</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Acute Versus Staged PCI for Lesions With FFR ≤ 0.80</title>
          <description>Comparison of acute versus staged PCI treatment for lesions with FFR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Comparison of PCI vs Medical Therapy in FFR Negative Lesions</title>
        <description>comparison of patients receiving staged PCI treatment of FFR-negative lesions in the non-IRA (decision made by referring physician who was blinded to FFR results) and patients receiving medical therapy for FFR-negative lesions in the non-IRA</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR- Lesions Treated With PCI</title>
            <description>patients receiving staged PCI treatment of FFR-negative lesions in the non-IRA (decision made by referring physician who was blinded to FFR results)</description>
          </group>
          <group group_id="O2">
            <title>FFR- Lesions Treated With Medical Therapy</title>
            <description>patients receiving medical therapy for FFR-negative lesions in the non-IRA</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of PCI vs Medical Therapy in FFR Negative Lesions</title>
          <description>comparison of patients receiving staged PCI treatment of FFR-negative lesions in the non-IRA (decision made by referring physician who was blinded to FFR results) and patients receiving medical therapy for FFR-negative lesions in the non-IRA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Per Protocol Analysis - Occurence of MACCE at 3 Year</title>
        <description>post-hoc, per-protocol analysis, 328 underwent FFR-guided complete revascularization and 550 patients underwent IRA-only treatment, occurence of MACCE at 3 year</description>
        <time_frame>3 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FFR Guided Complete Revascularisation</title>
            <description>Patients who underwent FFR guided complete revascularisation</description>
          </group>
          <group group_id="O2">
            <title>IRA Only Treatment</title>
            <description>Patients who underwent IRA only treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Per Protocol Analysis - Occurence of MACCE at 3 Year</title>
          <description>post-hoc, per-protocol analysis, 328 underwent FFR-guided complete revascularization and 550 patients underwent IRA-only treatment, occurence of MACCE at 3 year</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 year</time_frame>
      <desc>Only Cardiac Serious Adverse Event data are available.</desc>
      <group_list>
        <group group_id="E1">
          <title>FFR-guided Revascularisation Strategy</title>
          <description>In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of &gt;0.80 will not be treated.
FFR-guided revascularisation strategy: FFR-guided revascularisation strategy</description>
        </group>
        <group group_id="E2">
          <title>Randomised to Guidelines Group</title>
          <description>In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
randomised to guidelines group: Staged revascularisation by proven ischemia or persistence of symptoms of angina</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="590"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="308" subjects_at_risk="590"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="295"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="590"/>
              </event>
              <event>
                <sub_title>PCI</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="295"/>
                <counts group_id="E2" events="144" subjects_affected="144" subjects_at_risk="590"/>
              </event>
              <event>
                <sub_title>Coronary Artery Bypass graft</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="590"/>
              </event>
              <event>
                <sub_title>Stent Thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="295"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="590"/>
              </event>
              <event>
                <sub_title>Cardiac Hospitalisations</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="295"/>
                <counts group_id="E2" events="87" subjects_affected="87" subjects_at_risk="590"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="590"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="590"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>any bleeding</sub_title>
                <description>any bleeding</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="295"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="590"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Pieter Smits</name_or_title>
      <organization>Maasstad Hospital</organization>
      <phone>+31102913322</phone>
      <email>SmitsP@maasstadziekenhuis.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

